Developing Supercharged T cell Therapies
We are focused on T cell therapy, a promising modality that holds the potential to generate transformational responses in patients with solid tumors. By armoring T cells with the most advanced enhancements in a single T cell, T-knife is designing T cell therapies to achieve a clinically meaningful impact for patients.
Engineering next-generation, best-in-class T cell therapies
Advancing portfolio of T cell therapies for solid tumors
T-knife’s unique approach leverages proprietary platforms and synthetic biology capabilities to design the next-generation of supercharged T cells with best-in-class potential. T-knife’s product candidates are designed to induce an organically optimized immune signaling cascade intended to stimulate a potent T cell-driven immune response. Our T cell therapies target tumor antigens in multiple, difficult to treat solid tumor indications.
TK-6302 is T-knife’s lead product candidate targets PRAME, an antigen expressed in a number of solid tumor indications with high unmet medical need. As shown in a complex 3-dimensional (3D) spheroid tumor model, TK-6302 destroys multiple rounds of tumors, while control T cells are ineffective. Following CTA approval, a Phase 1 trial is planned to begin in 2026.